<DOC>
	<DOCNO>NCT02651441</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy chemotherapy combine dendritic activate cytokine-induced killer cell ( D-CIK ) non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>D-CIK Combined With Chemotherapy Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>60 patient stage Ⅲb～Ⅳ NSCLC randomly divide group A（receive D-CIK treatment chemotherapy ) group B（just receive chemotherapy ) , randomize ratio 1:1 . Patients group A receive 3 cycle D-CIK treatment ( every 1 month ) 4 cycle chemotherapy ( every 2 week ) .Patients group B receive 4 cycle chemotherapy（every 2 week ) .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>The patient sing informed consent ; Histologically confirm NSCLC stage Ⅲb～Ⅳ ; Expected survival time 2 month ; Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Hemoglobin＜8.0 g/dL , White blood cell ＜3 x 10^9/L ; Platelet count ＜75 x 10^9/L ; ALT , AST , BUN Cr normal limit 3.0 time ; Known suspect allergy investigational agent agent give association trial ; Pregnant lactating patient ; Known history Human Immunodeficiency Virus ( HIV ) , Hepatitis C Virus ( HCV ) TreponemaPallidun ( TP ) infection ; Patients suffer serious autoimmune disease ; Patients use long time use immunosuppressant ; Patients active infection ; Patients suffer serious organ dysfunction ; Patients suffer cancer ; Other situation researcher consider unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>D-CIK</keyword>
	<keyword>lung cancer</keyword>
</DOC>